Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance

6. McKesson Corporation (NYSE:MCK)

Number of Hedge Fund Holders In Q1 2025: 78

McKesson Corporation (NYSE:MCK) is one of the largest healthcare services providers in America. In his earlier comments about the company, Cramer discussed that regulatory challenges could continue to deal significant blows to the firm and its peers. McKesson Corporation (NYSE:MCK)’s stock has gained 26% year-to-date despite falling by 8.9% in April after the Liberation Day tariff announcements. The stock has performed well due to multiple catalysts, such as strong earnings reports and dividend increases. Here is what Cramer said about McKesson Corporation (NYSE:MCK):

“No I mean look it’s not the hospitals which always win and it’s certainly not the middlemen. . .And if you told me McKesson was down three quarters, I’d say well fill her up.”

Previously, he mentioned McKesson Corporation (NYSE:MCK) shares and the potential of government action:

“These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they’re some of the best performers out there, and they’ve done great this year, as is pretty much always the case. And yet, doesn’t it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum.

I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don’t live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what’s known as the Most-Favored-Nation pricing for Medicare…

As a result, all the drug distributors are either flat or slightly lower this week… so that’s the conundrum with these middlemen, Cardinal, Cencora, and McKesson are all doing incredibly well, but like I said before, there always seems to be a threat that they could be regulated out of existence.”